Cancer therapy and cachexia

Area of Science:

• Oncology
• Metabolism
• Physiology

Background:

• Cancer therapy aims to eliminate tumors but can cause significant side effects.
• Cancer-associated cachexia is a complex syndrome involving weight loss, inflammation, and metabolic changes.
• Emerging evidence suggests cancer treatments can directly contribute to or worsen cachexia.

Purpose of the Study:

• To investigate the intersection between cancer therapeutic interventions and the pathophysiology of cachexia.
• To explore how treatments impact key organ systems involved in cachexia.
• To highlight the need for integrated clinical trial endpoints.

Main Methods:

• Review of literature on cancer therapies and cachexia mechanisms.
• Focus on the effects of chemotherapy and targeted treatments.
• Examination of molecular pathways (e.g., IL-6, GDF-15, NF-κB, PKA/CREB) in affected organs.

Main Results:

• Cancer therapies can upregulate factors like IL-6 and GDF-15, leading to reduced appetite and negative energy balance.
• Treatments can activate signaling pathways (NF-κB, PKA/CREB) in muscle and adipose tissue, contributing to atrophy.
• Therapeutic interventions share biological pathways with cancer progression in driving cachexia.

Conclusions:

• Cancer therapies can exacerbate cachexia through direct effects on organ systems.
• Understanding treatment timing and modality is key to managing cachexia.
• Clinical trials should include physiological endpoints to assess overall patient well-being and therapeutic impact.